Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: A novel role of AR mutation for prostate cancer development

FASEB Journal

Volumn 22, Issue 4, 2008, Pages 1258-1267

  Moehren, Udo ^a   Papaioannou, Maria ^b   Reeb, Christina A ^b   Grasselli, Annalisa ^c   Nanni, Simona ^c   Asim, Mohammad ^b   Roell, Daniela ^b   Prade, Ina ^b   Farsetti, Antonella ^c,d   Baniahmad, Aria ^a,e,f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Institute of Human Genetics and Anthropology   (Germany)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f Med Fac   (Germany)

Author keywords

Agonist; Antagonist; Chromatin; Gene silencing; Transrepression

Indexed keywords

AMINO ACID; ANDROGEN RECEPTOR; ANTIANDROGEN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; GENE REPRESSION; GENETIC TRANSCRIPTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MUTATION; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; PROTEIN SUBUNITS; RECEPTORS, ANDROGEN; TELOMERASE; TRANS-ACTIVATION (GENETICS);

EID: 42049105132     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-9360com     Document Type: Article

References (46)

1. Hoffman, M. A., DeWolf, W. C., and Morgentaler, A. (2000) Is low serum free testosterone a marker for high grade prostate cancer? J. Urol. 163, 824-827
2. Slater, S., and Oliver, R. T. (2000) Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 17, 431-439
3. Schatzl, G., Madersbacher, S., Thurridl, T., Waldmuller, J., Kramer, G., Haitel, A., and Marberger, M. (2001) High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47, 52-58
4. Dai, W. S., Kuller, L. H., LaPorte, R. E., Gutai, J. P., Falvo-Gerard, L., and Caggiula, A. (1981) The epidemiology of plasma testosterone levels in middle-aged men. Am. J. Epidemiol. 114, 804-816
5. Morley, J. E., Kaiser, F. E., Perry, H. M., 3rd, Patrick, P., Morley, P. M., Stauber, P. M., Vellas, B., Baumgartner, R. N., and Garry, P. J. (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46, 410-413
6. Abate-Shen, C., and Shen, M. M. (2000) Molecular genetics of prostate cancer. Genes Dev. 14, 2410-2434
7. Comhaire, F. H. (2000) Andropause: hormone replacement therapy in the ageing male. Eur. Urol. 38, 655-662
8. Teske, E., Naan, E. C., van Dijk, E. M., Van Garderen, E., and Schalken, J. A. (2002) Canine prostate carcinoma: epidemiological evidence of an increased risk in castrated dogs. Mol. Cell. Endocrinol. 197, 251-255
9. Prehn, R. T. (1999) On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 59, 4161-4164
10. Chatterjee, B. (2003) The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol. Cell. Biochem. 253, 89-101
11. Artandi, S. E., and DePinho, R. A. (2000) A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr. Opin. Genet. Dev. 10, 39-46
12. Geserick, C., Tejera, A., Gonzalez-Suarez, E., Klatt, P., and Blasco, M. A. (2006) Expression of mTERT in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor-beta signaling. Oncogene 25, 4310-4319
13. Smith, L. L., Coller, H. A., and Roberts, J. M. (2003) Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat. Cell Biol. 5, 474-479
14. Sommerfeld, H. J., Meeker, A. K., Piatyszek, M. A., Bova, G. S., Shay, J. W., and Coffey, D. S. (1996) Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 56, 218-222
15. Zhang, W., Kapusta, L. R., Slingerland, J. M., and Klotz, L. H. (1998) Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 58, 619-621
16. Biroccio, A., and Leonetti, C. (2004) Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocr. Relat. Cancer 11, 407-421
17. Kim, N. W., and Hruszkewycz, A. M. (2001) Telomerase activity modulation in the prevention of prostate cancer. Urology 57, 148-153
18. Lichtsteiner, S. P., Lebkowski, J. S., and Vasserot, A. P. (1999) Telomerase: a target for anticancer therapy. Ann. N. Y. Acad. Sci. 886, 1-11
19. Guo, C., Armbruster, B. N., Price, D. T., and Counter, C. M. (2003) In vivo regulation of hTERT expression and telomerase activity by androgen. J. Urol. 170, 615-618
20. Schindler, A., Fiedler, U., Meye, A., Schmidt, U., Fussel, S., Pilarsky, C., Herrmann, J., and Wirth, M. P. (2001) Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro. Int. J. Oncol. 19, 25-30
21. Janknecht, R. (2004) On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett. 564, 9-13
22. Culig, Z., Klocker, H., Bartsch, G., and Hobisch, A. (2002) Androgen receptors in prostate cancer. Endocr. Relat. Cancer 9, 155-170
23. Meeker, A. K., Sommerfeld, H. J., and Coffey, D. S. (1996) Telomerase is activated in the prostate and seminal vesicles of the castrated rat. Endocrinology 137, 5743-5746
24. Ravindranath, N., Ioffe, S. L., Marshall, G. R., Ramaswamy, S., Plant, T. M., and Dym, M. (2001) Androgen depletion activates telomerase in the prostate of the nonhuman primate, Macaca mulatta. Prostate 49, 79-89
25. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B., and Balk, S. P. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59, 2511-2515
26. Dotzlaw, H., Moehren, U., Mink, S., Cato, A. C., Iniguez Lluhi, J. A., and Baniahmad, A. (2002) The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol. Endocrinol. 16, 661-673
27. Cong, Y. S., Wen, J., and Bacchetti, S. (1999) The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Genet. 8, 137-142
28. Misiti, S., Nanni, S., Fontemaggi, G., Cong, Y. S., Wen, J., Hirte, H. W., Piaggio, G., Sacchi, A., Pontecorvi, A., Bacchetti, S., and Farsetti, A. (2000) Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol. Cell. Biol. 20, 3764-3771
29. Fronsdal, K., Engedal, N., and Saatcioglu, F. (2000) Efficient DNA-mediated gene transfer into prostate cancer cell line LNCaP. Prostate 43, 111-117
30. Moehren, U., Papaioannou, M., Reeb, C. A., Hong, W., and Baniahmad, A. (2007) Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth. Mol. Endocrinol. 21, 1039-1048
31. Nanni, S., Priolo, C., Grasselli, A., D'Eletto, M., Merola, R., Moretti, F., Gallucci, M., De Carli, P., Sentinelli, S., Cianciulli, A. M., Mottolese, M., Carlini, P., Arcelli, D., Helmer-Citterich, M., Gaetano, C., Loda, M., Pontecorvi, A., Bacchetti, S., Sacchi, A., and Farsetti, A. (2006) Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol. Cancer Res. 4, 79-92
32. Balk, S. P. (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology 60, 132-138; discussion 138-139
33. Shibata, H., Spencer, T. E., Onate, S. A., Jenster, G., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (1997) Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res. 52, 141-164; discussion 164-145
34. Kallio, P. J., Poukka, H., Moilanen, A., Janne, O. A., and Palvimo, J. J. (1995) Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element. Mol. Endocrinol. 9, 1017-1028
35. Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Dahl, D., Brufsky, A., Talcott, J., Hennekens, C. H., and Kantoff, P. W. (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 94, 3320-3323
36. Gast, A., Neuschmid-Kaspar, F., Klocker, H., and Cato, A. C. (1995) A single amino acid exchange abolishes dimerization of the androgen receptor and causes Reifenstein syndrome. Mol. Cell. Endocrinol. 111, 93-98
37. Xu, D., Wang, Q., Gruber, A., Bjorkholm, M., Chen, Z., Zaid, A., Selivanova, G., Peterson, C., Wiman, K. G., and Pisa, P. (2000) Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19, 5123-5133
38. Shenk, J. L., Fisher, C. J., Chen, S. Y., Zhou, X. F., Tillman, K., and Shemshedini, L. (2001) p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J. Biol. Chem. 276, 38472-38479
39. Soda, H., Raymond, E., Sharma, S., Lawrence, R., Davidson, K., Oka, M., Kohno, S., Izbicka, E., and Von Hoff, D. D. (2000) Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro. Prostate 43, 161-168
40. Kang, Z., Janne, O. A., and Palvimo, J. J. (2004) Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol. Endocrinol. 18, 2633-2648
41. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A., and Mulder, E. (1992) Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31, 2393-2399
42. Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., and Klocker, H. (1999) Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer 81, 242-251
43. Metivier, R., Reid, G., and Gannon, F. (2006) Transcription in four dimensions: nuclear receptor-directed initiation of gene expression. EMBO Rep. 7, 161-167
44. He, B., Kemppainen, J. A., and Wilson, E. M. (2000) FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 275, 22986-22994
45. Schneikert, J., Peterziel, H., Defossez, P. A., Klocker, H., Launoit, Y., and Cato, A. C. (1996) Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J. Biol. Chem. 271, 23907-23913
46. Fu, M., Wang, C., Wang, J., Zhang, X., Sakamaki, T., Yeung, Y. G., Chang, C., Hopp, T., Fuqua, S. A., Jaffray, E., Hay, R. T., Palvimo, J. J., Janne, O. A., and Pestell, R. G. (2002) Androgen receptor acetylation governs trans- activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol. Cell. Biol. 22, 3373-3388